{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:33:18Z","timestamp":1780471998368,"version":"3.54.1"},"reference-count":76,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>We review the latest guidelines and note special considerations for systemic lupus erythematosus (SLE) patients when approaching vaccination against SARS-CoV-2, influenza, pneumococcus, herpes zoster, and potentially respiratory syncytial virus (RSV) vaccine in the future.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>SLE patients have unique infectious risks due to newer treatments and the nature of the disease itself. It is important to balance the benefit of additional protective immunity from updated vaccines against the possible risk of disease activity exacerbations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>It is important to continuously evaluate the safety and immunogenicity of updated vaccines specifically for SLE patients. Additionally, the newly approved RSV vaccine should be considered for this population to reduce severe respiratory illness.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000992","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T17:08:03Z","timestamp":1700240883000},"page":"148-153","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Vaccination updates and special considerations for systemic lupus erythematosus patients"],"prefix":"10.1097","volume":"36","author":[{"given":"Jammie","family":"Law","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sorrento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5152\/eurjrheum.2023.23068","article-title":"Infections in patients with systemic lupus erythematosus: the contribution of primary immune defects versus treatment-induced immunosuppression","volume":"10","author":"Kunzler","year":"2023","journal-title":"Eur J Rheumatol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/acr.24628","article-title":"Avoidable acute care use for vaccine-preventable illnesses among Medicaid beneficiaries with lupus","volume":"73","author":"Feldman","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.semarthrit.2020.06.004","article-title":"Clinical characteristics and risk factors of infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis of observational studies","volume":"50","author":"Yuan","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3390\/vaccines11040760","article-title":"Influenza, pneumococcal and herpes zoster vaccination rates in patients with autoimmune inflammatory rheumatic diseases","volume":"11","author":"Krasselt","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0889-857X(02)00100-X","article-title":"Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis\/dermatomyositis","volume":"29","author":"Juarez","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"e002187","DOI":"10.1136\/rmdopen-2021-002187","article-title":"SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry","volume":"8","author":"Liew","year":"2022","journal-title":"RMD Open"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/S2665-9913(23)00004-8","article-title":"Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study","volume":"5","author":"Md Yusof","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/art.42372","article-title":"American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 5","volume":"75","author":"Curtis","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1136\/annrheumdis-2021-222006","article-title":"EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update","volume":"81","author":"Landewe","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"e002839","DOI":"10.1136\/rmdopen-2022-002839","article-title":"Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study","volume":"9","author":"Jiang","year":"2023","journal-title":"RMD Open"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/art.41937","article-title":"Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination","volume":"74","author":"Izmirly","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"102959","DOI":"10.1016\/j.jaut.2022.102959","article-title":"PostmRNA vaccine flares in autoimmune inflammatory rheumatic diseases: results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING)","volume":"134","author":"Ma","year":"2023","journal-title":"J Autoimmun"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s10067-021-05980-5","article-title":"Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus","volume":"41","author":"Zavala-Flores","year":"2022","journal-title":"Clin Rheumatol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/rheumatology\/keac661","article-title":"Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study","volume":"62","author":"Naveen","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"e613","DOI":"10.1016\/S2665-9913(21)00221-6","article-title":"Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study","volume":"3","author":"Felten","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s10067-021-05963-6","article-title":"Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus","volume":"41","author":"Barbhaiya","year":"2022","journal-title":"Clin Rheumatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/vaccines10050663","article-title":"The idmpact of Anti-SARS-CoV-2 vaccine in patients with systemic lupus erythematosus: a multicentre cohort study","volume":"10","author":"Gerosa","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00296-023-05347-w","article-title":"Predictors of a weak antibody response to COVID-19 mRNA vaccine in systemic lupus erythematosus","volume":"43","author":"Parsons","year":"2023","journal-title":"Rheumatol Int"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/acr.25094","article-title":"Effect of systemic lupus erythematosus and immunosuppressive agents on COVID-19 vaccination antibody response","volume":"75","author":"Petri","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/annrheumdis-2022-222498","article-title":"Severely impaired humoral response against SARS-CoV-2 variants of concern following two doses of BNT162b2 vaccine in patients with systemic lupus erythematosus (SLE)","volume":"81","author":"Mageau","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"e582","DOI":"10.1016\/S2665-9913(22)00190-4","article-title":"Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City","volume":"4","author":"Saxena","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R23-20250526","first-page":"676","article-title":"Immunogenicity and risk of disease flare after a three-dose regimen with SARS-CoV-2 vaccination in patients with systemic lupus erythematosus: results from the prospective cohort study COVAC-SLE","volume":"41","author":"Larsen","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/09612033221151012","article-title":"Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab","volume":"32","author":"Schiavoni","year":"2023","journal-title":"Lupus"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/jcm12031083","article-title":"Humoral and T-cell mediated response after the third dose of mRNA vaccines in patients with systemic lupus erythematosus on belimumab","volume":"12","author":"Quartuccio","year":"2023","journal-title":"J Clin Med"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"e000726","DOI":"10.1136\/lupus-2022-000726","article-title":"Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis","volume":"9","author":"Assawasaksakul","year":"2022","journal-title":"Lupus Sci Med"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology Guideline for Vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2018-213222","article-title":"Impact of temporary methotrexate discontinuation for 2\u200aweeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.42318","article-title":"A multicenter, prospective, randomized, parallel-group trial on the effects of temporary methotrexate discontinuation for one week versus two weeks on seasonal influenza vaccination in patients with rheumatoid arthritis","volume":"75","author":"Park","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/acr.20465","article-title":"Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases","volume":"63","author":"Elkayam","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/rheumatology\/kep200","article-title":"Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study","volume":"48","author":"Holvast","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.amjmed.2021.08.038","article-title":"Influenza vaccination in systemic lupus erythematosus: efficacy, effectiveness, safety, utilization, and barriers","volume":"135","author":"Sim","year":"2022","journal-title":"Am J Med"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1177\/09612033211040371","article-title":"Influenza A\/Singapore (H3N2) component vaccine in systemic lupus erythematosus: a distinct pattern of immunogenicity","volume":"30","author":"Claudino Formiga","year":"2021","journal-title":"Lupus"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/rheumatology\/ker427","article-title":"Influenza A\/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?","volume":"51","author":"Borba","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3899\/jrheum.111587","article-title":"Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial","volume":"39","author":"Chatham","year":"2012","journal-title":"J Rheumatol"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/ard.2011.150250","article-title":"Immunogenicity and safety of the 2009 nonadjuvanted influenza A\/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases","volume":"70","author":"Saad","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R38-20250526","first-page":"ciad477","article-title":"Immunogenicity of high-dose vs. MF59-adjuvanted vs. standard influenza vaccine in solid organ transplant recipients: the STOP-FLU trial","author":"Mombelli","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/j.ajkd.2022.01.425","article-title":"Seroresponse to inactivated and recombinant influenza vaccines among maintenance hemodialysis patients","volume":"80","author":"Manley","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"e1456","DOI":"10.1002\/cti2.1456","article-title":"Robust immunity to influenza vaccination in haematopoietic stem cell transplant recipients following reconstitution of humoral and adaptive immunity","volume":"12","author":"Zhang","year":"2023","journal-title":"Clin Transl Immunology"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2665-9913(19)30094-3","article-title":"Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial","volume":"2","author":"Colmegna","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"999704","DOI":"10.3389\/fimmu.2022.999704","article-title":"Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials","volume":"13","author":"Steiger","year":"2022","journal-title":"Front Immunol"},{"key":"R43-20250526","first-page":"road092","article-title":"The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled Phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1177\/0961203314543918","article-title":"Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections","volume":"23","author":"Luijten","year":"2014","journal-title":"Lupus"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jbspin.2017.05.012","article-title":"Pneumococcal infection in patients with systemic lupus erythematosus","volume":"85","author":"Schurder","year":"2018","journal-title":"Joint Bone Spine"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"1018899","DOI":"10.3389\/fpubh.2022.1018899","article-title":"A survey of systemic lupus erythematosus patients\u2019 attitudes toward influenza and pneumococcal vaccination in Southwest China","volume":"10","author":"Chen","year":"2022","journal-title":"Front Public Health"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"50","DOI":"10.14412\/1996-7012-2021-3-50-56","article-title":"Safety and efficacy of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus","volume":"15","author":"Tarasova","year":"2021","journal-title":"Modern Rheumatology Journal"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/kew211","article-title":"Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis","volume":"55","author":"Puges","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/0961203316636472","article-title":"Immunogenicity of pneumococcal polysaccharide vaccine in adult systemic lupus erythematosus patients undergoing immunosuppressive treatment","volume":"25","author":"Rezende","year":"2016","journal-title":"Lupus"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1016\/j.vaccine.2017.07.094","article-title":"Pneumococcal vaccination in patients with systemic lupus erythematosus: a multicenter placebo-controlled randomized double-blind study","volume":"35","author":"Grabar","year":"2017","journal-title":"Vaccine"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.autrev.2018.08.002","article-title":"Immunogenicity, safety and tolerability of antipneumococcal vaccination in systemic lupus erythematosus patients: an evidence-informed and PRISMA compliant systematic review and meta-analysis","volume":"18","author":"Adawi","year":"2019","journal-title":"Autoimmun Rev"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/annrheumdis-2018-214888","article-title":"Revisiting the issue of how to assess pneumococcal vaccine immunogenicity: a post hoc analysis of antipneumococcal antibody responses among adult patients with systemic lupus erythematosus previously immunised with 23-valent pneumococcal polysaccharide vaccine","volume":"78","author":"Rezende","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1177\/09612033231153535","article-title":"Combined 13-valent pneumococcal conjugate and 23-valent pneumococcal polysaccharide vaccine regimens for adults with systemic lupus erythematosus: does the sequence of pneumococcal vaccination affect immunogenicity responses? A single-center cohort study in Brazil","volume":"32","author":"Rezende","year":"2023","journal-title":"Lupus"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"6859","DOI":"10.1016\/j.vaccine.2020.08.065","article-title":"Serum IgG2 levels predict long-term protection following pneumococcal vaccination in systemic lupus erythematosus (SLE)","volume":"38","author":"Gerard","year":"2020","journal-title":"Vaccine"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1136\/annrheumdis-2017-212789","article-title":"Impaired long-term immune protection following pneumococcal 13-valent\/23-valent polysaccharide vaccine in systemic lupus erythematosus (SLE)","volume":"77","author":"Sacre","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1177\/0961203317695465","article-title":"Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine","volume":"26","author":"Nagel","year":"2017","journal-title":"Lupus"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/0961203317703495","article-title":"A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus","volume":"26","author":"Chatham","year":"2017","journal-title":"Lupus"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13075-020-2124-3","article-title":"Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients","volume":"22","author":"Nived","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial","volume":"70","author":"Vink","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and posthoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/0961203312470186","article-title":"Increased incidence of herpes zoster among patients with systemic lupus erythematosus","volume":"22","author":"Chakravarty","year":"2013","journal-title":"Lupus"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jaad.2015.12.059","article-title":"Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): a nationwide case-control study","volume":"75","author":"Hu","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"e000464","DOI":"10.1136\/lupus-2020-000464","article-title":"Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials","volume":"8","author":"Tummala","year":"2021","journal-title":"Lupus Sci Med"},{"key":"R71-20250526","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3899\/jrheum.130170","article-title":"Herpes zoster vaccination in SLE: a pilot study of immunogenicity","volume":"40","author":"Guthridge","year":"2013","journal-title":"J Rheumatol"},{"key":"R72-20250526","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/art.42261","article-title":"Recombinant zoster vaccine uptake and risk of flares among older adults with immune-mediated inflammatory diseases in the US","volume":"74","author":"Leung","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R73-20250526","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1093\/rheumatology\/keab139","article-title":"Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients","volume":"60","author":"Lenfant","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R74-20250526","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/acr2.11150","article-title":"Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center's experience with 400 patients","volume":"2","author":"Stevens","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"R76-20250526","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.3390\/pathogens11111324","article-title":"Going Viral-RSV as the neglected adult respiratory virus","volume":"11","author":"Busack","year":"2022","journal-title":"Pathogens"},{"key":"R77-20250526","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.3324\/haematol.2018.215152","article-title":"Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies","volume":"104","author":"Khawaja","year":"2019","journal-title":"Haematologica"},{"key":"R78-20250526","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/cid\/ciab595","article-title":"Incidence of respiratory syncytial virus infection among hospitalized adults, 2017\u20132020","volume":"74","author":"Branche","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R79-20250526","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/infdis\/jiab612","article-title":"A randomized phase 1\/2 study of a respiratory syncytial virus prefusion F vaccine","volume":"225","author":"Walsh","year":"2022","journal-title":"J Infect Dis"},{"key":"R80-20250526","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:16:14Z","timestamp":1748294174000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000992","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}